Letrozole
HNSCC
Dan ZandbergSmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the HNSCC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Dan Zandberg | Phase 2 | B |
Eftilagimod Alfa Immutep S.A.S. | Phase 2 | B |
Rosiglitazone Dan Zandberg | Phase 2 | CCC |
IRON(II) SULPHATE (1:1), HEPTAHYDRATE Sichuan Enray Pharmaceutical Sciences Company | Phase 2 | CCC |
Carbon Nanoparticle Suspension Sichuan Enray Pharmaceutical Sciences Company | Phase 2 | CCC |
View all 24 →
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →